

Table 5. Comparison of costs for the treatment under consideration and its comparators

	Medicine acquisition	Medicine administration	Healthcare resource	Adverse event	Total costs (41 patients)
Neoadjuvant nivolumab plus ipilimumab	£££	£46,115	£76,726	£6,975	£££
NHS Wales SOC	£££	£82,560	£95,340	£1,144	£££
Cost difference	£££	£36,445	£18,614	-£5,831	£££(cost saving)

£££: commercial in confidence figure removed

Calculations are based on 41 patients.

Costs exclude VAT.

Patient Access Scheme prices used.

SOC: standard of care, as outlined in Appendix 3.